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Objective: To compare the clinical and economic effects of a strategy using
immediate endoscopy to a non-invasive strategy utilizing a serologic test for
Helicobacterpylori infection for individuals with symptoms suggestive ofpep-
tic ulcer disease.
Design: Cost-effectiveness analysis evaluating the clinical and economic effects
of alternative management strategies of hypothetical patients with suspected
peptic ulcer disease in a computer simulation model.
Intervention: Two strategies for hypothetical patients with suspected ulcer dis-
ease were evaluated: 1) Immediate endoscopy and biopsy for H. pylori, using
antisecretory treatment in all patients with documented ulcers and adding
antibiotic eradication therapy for those patients with ulcers whosebiopsies were
positive forH. pylori. 2) Empiric treatment with antisecretory therapy and sero-
logic testing for H. pylori for all patients, using antibiotic eradication therapy
only in patients testing positive for H. pylori.
Measurements: Cost per ulcer cured over a one-year study period.
Results: The more cost-effective strategy was the test-and-treat strategy
(Strategy 2) with $4481 cost per ulcer cured. The immediate endoscopy strate-
gy resulted in $8045 cost per ulcer cured. The cost-effectiveness advantage of
the non-invasive strategy diminished as the cost of endoscopy fell or as the
probability of recurrent symptoms rose in patients initially managed without
endoscopy.
Conclusion: Endoscopy, though costly, precisely guided diagnosis and treat-
ment and, thus, potentially reduced the numberofpatients inappropriately treat-
ed. However, cost-effectiveness analysis supports the continued practice of ini-
tial non-invasive management of patients with symptoms suggestive of peptic
ulcer disease, achieving the benefits ofH. pylori eradication through the use of
serologic testing to guide antibiotic use.
INTRODUCTION
Empiric antisecretory therapy has been widely recommended as the initial manage-
ment for patients presenting with presumed peptic ulcer disease, with endoscopic evalua-
tion reserved for persistent or recurrent symptoms [1]. However, the association between
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Helicobacter pylori and peptic ulcer disease compels rethinking of the management of
this common clinical condition [2-3]. While elimination ofthe organism slightly improves
ulcer healing rates, the principal benefit is the dramatic reduction in ulcer recurrence rates
in those patients in whom the infection has been successfully eradicated [4-5]. In order to
minimize inappropriate use of antibiotic therapy, guidelines such as those of an NIH
Consensus Panel recommend a strategy that requires the objective documentation of an
active ulcer and H. pylori infection prior to prescription of antibiotic treatment [6].
Such a recommendation makes two assumptions. First, that diagnostic confirmation
ofboth ulcer disease and H. pylori infection is the optimal strategy after careful consider-
ation of benefits, risks and costs of available alternatives. Second, that community physi-
cians, who are accustomed to using initial empiric therapy in patients with ulcer-like
symptoms, will find this guideline instructive in their clinical practice. Accordingly, the
objective of our study was to use decision analytic techniques to assess the impact of a




The details ofthe decision analytic model used in this study have been published pre-
viously elsewhere [7]. Using a decision analysis software program, Decision Maker 7.0
(Pratt Medical Group, Boston, Massachusetts), a simulation was constructed to predict the
natural history of peptic ulcer disease, its interaction with H. pylori infection and the
effects of various diagnostic and therapeutic medical interventions. The analysis started
with a cohort of 1000 hypothetical patients presenting to a physician with symptoms sug-
gestive of peptic ulcer disease who were not concurrently taking NSAIDSd. On entry to
the simulation, all of the hypothetical patients had symptoms of sufficient severity to jus-
tify an empiric course of antisecretory agents and no previously documented peptic ulcer
disease.
Management strategies evaluated
1) Immediate endoscopy and biopsy for H. pylori: All patients underwent immedi-
ate endoscopy and biopsy for H. pylori. Patients with an active ulcer detected by
endoscopy were prescribed antisecretory therapy. Antibiotic therapy was limited to those
individuals with both an ulcer and evidence ofH. pylori infection found upon biopsy.
2) Empiric treatment with antisecretory therapy and serologic testing for H. pylori:
This strategy did not require diagnostic confirmation of an ulcer prior to the initiation of
H. pylori eradication therapy. Every hypothetical patient was prescribed an empiric course
of antisecretory agents, and in the computer simulation, underwent a qualitative H. pylori
serologic test at the initial medical encounter. Only patients with a positive serologic test
received antibiotic therapy.
Resource utilization such as physician visits, pharmaceutical use, procedures and hos-
pitalizations were captured by the model. Each patient was evaluated in the model at six-
week intervals for one year for the presence or absence of three clinical conditions on
which all further interactions with the medical care system were based: recurrent symp-
toms, H. pylori infection and active ulcer disease. Patients whose symptoms were caused
by reasons other than peptic ulcer disease were captured in the simulation up to and
including the point at which they were objectively identified as not having an ulcer on
endoscopic evaluation.
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CLINICAL CONDITIONS AND SUBSEQUENT INTERVENTION
Recurrent Symptoms
After the initial intervention, every simulated patient with persistent or recurrent
ulcer-like symptoms was assumed to return for medical evaluation. Those individuals ini-
tially managed non-invasively (Strategy 2) underwentendoscopy with biopsy forH. pylori
infection on the first return visit for recurrent symptoms. All subsequent treatments were
based on the endoscopy results and biopsy findings.
H. pylori Infection
Data from epidemiological investigations suggest that H. pylori is an infection of
childhood to which a lifetime of immunological response is produced. Serological tests
are available that qualitatively and quantitatively assess the presence or absence of anti-
bodies to H. pylori infection [8]. Although spontaneous elimination of the organism is
possible, in most instances the infection is lifelong in the absence of therapy intended to
specifically eradicate the organism. In the simulation, H. pyloriinfection affected the like-
lihood of ulcer recurrence but had no direct effect on the development or resolution of
symptoms.
If antibiotic therapy to eradicate H. pylori had not been prescribed previously, it was
presumed that active infection was present in individuals with the presence of a positive
qualitative antibody test. The serologic test was assumed to have95 percentsensitivity and
95 percent specificity [8]. Although antibody levels fall after eradication ofthe organism,
they remain detectable in the serum in many instances. The persistence ofH. pylori anti-
bodies after eradication considerably diminishes the value of qualitative serology in
assessing whether infection has been cured, in that a positive test can indicate eitherpast
or ongoing infection. Thus, in the simulation, a qualitative serologic test was used only in
those patients who had not previously received H. pylori eradication therapy.
Once eradication therapy was prescribed, either biopsy for H. pylori or a urea breath
test was used to confirm cure or establish ongoing H. pylori infection. If endoscopy and
biopsy were not to be performed for a specific symptomatic encounter, a urea breath test
was undertaken to evaluate the effectiveness in eradicating H. pylori. Individuals who
failed to clearH. pylori after three courses ofantibiotic therapy were assumed to beinfect-
ed for theremainder ofthe study period. Once cleared ofH. pylori, infection was assumed
not to recur [9].
Successful eradication of H. pylori in patients with ulcers associated with non-
steroidal anti-inflammatory medications ordiagnoses other than active ulcer disease (e.g.,
gastritis) was assumed not to offer any benefit in terms ofreducing symptom severity or
preventing future ulcer development.
Active ulcer disease
Ulcer status determined the likelihood ofsymptomatic relieffrom therapy and, thus,
determined the need for future physician visits and related medical interventions.
Endoscopy was assumed to be a perfect test to diagnose ulcer disease and was presumed
to have no associated adverse events. Ulcer recurrence, not associated with NSAID use,
was related to H. pylori status and concurrent use of antisecretory therapy [5, 10].
Spontaneous ulcer development was assumed not to occur in patients whose initial symp-
toms were secondary to non-ulcer causes. Ulcers that failed to heal completely after three
courses of antisecretory therapy required maintenance antisecretory therapy for the dura-
tion ofthe study period.
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DATA SOURCES
Clinical Probabilities
A Medline search was conducted for English language articles to provide pertinent
clinical data for the simulation model. Bibliographies ofaccepted articles were reviewed
and a search of current issues of the peer-reviewed, general medicine, infectious disease
and gastroenterology literature was also undertaken to identify additional reports not
included in the computerized database. In instances of data unavailability or uncertainty,
unpublished data presented at the National Institutes of Health Consensus Development
Meeting were used [6]. Clinical input probabilities and ranges used in the simulation are
shown in Table 1.
Multiple antibiotic and antisecretory regimens of varying efficacy, cost, and compli-
ance were evaluated. The relatively small differences in ulcer healing and H. pylori erad-
ication rates among available regimens were investigated using sensitivity analysis.
Compliance and outcomes related to specific medication use, including antibiotic-related
adverse events, were incorporated into these analyses.
Table 1: Clinical inputs.
Clinical Probability Base Case Range
Active ulcer disease (%) 20 5-30
H. pylori infection ulcer present (%) 95 75-95
H. pylori infection ulcer absent (%) 50 20-60
Ulcer healing rate after antisecretory therapy (%) 75 50-90
H. pylori eradication after antibiotic course
(%) (includes compliance) 80 50-90
Recurrent symptom rate, active ulcer (%) 90 50-90
Recurrent symptom rate, healed ulcer (%) 10 0-30
Recurrent symptoms, no ulcer (%)/year 30 10-70
Ulcer recurrence, H. pyloni infection
(%)/100 patient months 2.7 2.0-6.6
Ulcer recurrence, no infection
(%)/100 patient months 0.6 0.1-2.0
Serious antibiotic complication per course (%) 0.5 0.1-1.0
Qualitative H. pylori serology test sensitivity 0.95 0.50-1.0
Qualitative H. pylori serology specificity 0.95 0.50-1.0
Table 2: Cost estimates
Intervention Base Case ($) Range ($)
Endoscopy 1180 200-2000
Biopsy for H. pylon 210 40-250
Antisecretory therapy (6 week course, full dose) 160 25-250
Maintenance antisecretory therapy (per month) 45 25-75
Antibiotic course (includes adverse events) 30 10-100
Qualitative H. pylori serology test 20 10-100
Urea breath test 200 50-200
Physician office visit 39 20-100
Hospitalization for ulcer complication, no surgery 7,095 6,000-12,000
Hospitalization for ulcer complication, surgery 24,081 17,500-38,000
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Cost Inputs
The perspective of the economic analysis was from that of the payer. Actual pay-
ments, not charges, for ambulatory services, inpatient care and physicians fees were
obtained from a large private third-party payer covering approximately three million per-
sons in the Eastern United States (Table 2). Given that variation in actual payments for
similar services exist by geographic region, we used the national average of charges
allowed by the Health Care Financing Administration for Medicare reimbursement to
determine the lower bound ofthe cost estimates.
SENSITIVITY ANALYSIS
Sensitivity analyses were performed to evaluate the effect of variations in clinical
probabilities and costestimates on the results. Thesereflect the ranges reported in the pub-
lished and unpublished literature (Tables 1 and 2). Only those input values whose inclu-
sion into the model would enhance the cost-effectiveness of the immediate endoscopy




The more cost-effective strategy was the non-invasive strategy incorporating serolog-
ic testing (Strategy 2) with $4481 cost per ulcer cured (Figure 1). The immediate
endoscopy strategy resulted in $8045 cost per ulcer cured. Given the high rate of symp-
toms in patients with active ulcer disease, nearly all (over 98 percent) active ulcers and
associated H. pylori infections were objectively diagnosed and treated by the end of the
study period in each strategy. The cost breakdown of various inputs to the cost per ulcer
cured is shown in Figure 2. While pharmaceutical costs per ulcer cured were $769 higher
for the non-invasive strategy, expenditures for endoscopy were $4606 lower, which more
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Figure 1. Cost per ulcer cured by management strategy.






















Figure 2. Cost breakdown per ulcer cured.
Sensitivity analysis
Examination ofclinical and costinputs overbroadranges revealed thatthe cost-effec-
tiveness advantage of non-invasive strategy (Strategy 2) relative to immediate endoscopy
(Strategy 1) was sensitive to only two variables: 1) cost of endoscopy and 2) probability
of recurrent symptoms in non-invasively treated patients in whom ulcer disease was not
the underlying cause oftheir symptoms.
As the cost ofendoscopy fell, the cost perpatient treated ofstrategies using immedi-
ate endoscopy approached that ofthe non-invasive strategies (Figure 3). Endoscopy costs,
inclusive ofpayments for professional fees and suite charges, must fall below $500 for an
equivalent cost-effectiveness ratio to result. The cost-effectiveness advantage ofnon-inva-
sive management was unchanged ifbiopsy were replaced by a less expensive CLO test.
0 Serologic test forH. py/on
_ Endoscopy and biopsy
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Cost of Endoscopy ($)







() $0 0 0 $0
192
I










0 0 10 20 30 40 50 60 70 80 90 100
Probability of Recurrent Symptoms
-0- Serologic test forH. pylori
0- Endoscopy and biopsy
Figure 4. Sensitivityanalysis: probability ofrecurrentsymptomsinpatientswithoutulcerdisease.
The other input variable found to be important in establishing an advantage for the
non-invasive strategies was the probability of recurrent symptoms in patients without
ulcer disease. Individuals without ulcer disease with recurrent symptoms after a course of
empiric therapy incurred the cost of invasive diagnostic testing (mandatory for recurrent
symptoms in all non-invasively treated patients) in addition to the cost of initial therapy.
Therefore, as the probability ofrecurrent symptoms rose in this population, the potential
savings ofinitial non-invasive management diminished as the use ofendoscopy increased.
As the annual recurrent symptom rate approached 80 percent, the cost per patient treated
of the non-invasive strategy approached that ofthe immediate endoscopy (Figure 4).
Sensitivity analysis which simultaneously varied the cost ofendoscopy and the prob-
ability ofrecurrent symptoms in non-ulcer patients was performed. This analysis revealed
that the choice of immediate endoscopy and biopsy (Strategy 1) versus test-and-treat
(Strategy 2) can be determined at different values of these clinical and economic inputs
(Figure 5).
DISCUSSION
In 1985, an American College of Physicians Position Paper supported empiric anti-
secretory therapy as the initial management for patients presenting with presumed peptic
ulcer disease, recommending endoscopy only in those individuals who failed an appro-
priate course of therapy [1]. The realization that acid suppression must be accompanied
by H. pylori eradication to prevent ulcerrecurrence, necessitates reevaluating this existing
treatment algorithm.
The NIH Consensus Panel Statement implicitly endorsed a strategy to document the
presence of both an ulcer and H. pylori infection prior to prescribing eradication therapy
[6]. The recommendation requiring confirmation of both diagnoses has raised consider-
able uncertainty among clinicians who have widely accepted an empiric first-line man-
agement of patients with presumed peptic ulcer disease. Compliance with the NIH
Consensus Panel recommendations would require increased invasive diagnostic testing
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Figure 5. Two variable sensitivity analysis: cost of endoscopy and probability of recurrent
symptoms in patients without ulcer disease. Area above solid line favors empiric therapy; area
below line favors immediate endoscopy.
prior to treatment, necessitating increased health system and patient-related costs to
achieve perfect diagnostic information.
Ourcost-effectiveness analysis supports the continued use ofanon-invasive treatment
strategy incorporating a serologic test for H. pylori infection at the first symptomatic
episode, changing somewhat the strategy ofinitial empiric H2 blocker therapy commonly
used in clinical practice. We recommend a single course ofempiric therapy guided by a
non-invasive serologic test for H. pylori. In our simulation, endoscopy was performed on
all patients who remained symptomatic or in whom symptoms recurred.
Although the cost-effectiveness ratios included antibiotic-related adverse events, the
analysis did not include the non-drug costs ofover-prescribing antibiotics which, in theo-
ry, increase the likelihood ofH. pylori resistance [11]. The issue ofbacterial resistance is
a real one when discussing broad use of antibiotics, especially when an important per-
centage ofpatients prescribed these agents may not receive clinical benefit, in that ulcer
disease was not the cause of the symptoms. At present, data are being collected to allow
quantification of antibiotic resistance. This calculation is complicated by the fact that all
of the antibiotic agents currently recommended (but not FDA approved) for treatment of
H. pylori are prescribed for other clinical indications.
Promotion of antibiotic resistance is not frequently considered in the individual
patient-physician episode of care, but is an important societal issue. Nonetheless, the
potential to maintain effective treatments in the future is of considerable importance.
Interestingly, antibiotic resistance to H. pylori may be viewed differently by clinicians, in
that whencompared to otherpathogens (e.g., S. aureus) H. pylori has arelatively low level
ofinfectiousness, and resultant infection does not cause significant morbidity in a major-
ity of cases.
The cost-effectiveness advantage for the non-invasive strategies over a strategy of
immediate endoscopy was sensitive to two inputs: the cost of endoscopy and the proba-
bility of recurrent symptoms leading to eventual endoscopy. Lower payments for
endoscopy, such as those found in competitive, managed care markets ordelivery systems
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outside the United States, may lead to a different strategy choice. Independent of
endoscopy cost, as the likelihood of eventual endoscopy increased, the savings achieved
by initially avoiding this diagnostic test was lost. A recent prospective trial from Denmark
comparing empiric H2 blocker therapy and immediate endoscopy reported that 65 percent
ofempirically treated patients with dyspepsia eventually underwent endoscopy, although
no attempts at H. pylori eradication were attempted [12]. At this rate of recurrent symp-
toms, the cost-effectiveness advantage of the initial non-invasive strategy was minimal
(Figure 4).
CONCLUSION
Endoscopy, though costly, precisely guides diagnosis and treatment and, thus, poten-
tially reduces the number ofpatients treated unnecessarily with antibiotics. However, our
cost-effectiveness analysis supports the continued practice of initial non-invasive man-
agement of patients with symptoms suggestive of peptic ulcer disease, but achieves the
benefits of H. pylori eradication through the use of serologic testing to guide antibiotic
use.
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